Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
FDA Draft Guidance on RUO/IUO Products Proposes Tough Changes for Industry Players
June 08, 2011
Given that RUO/IUO products are being marketed and used by life science players in numerous ways, the FDA's proposed restrictions will not be an easy task for industry to implement or for the agency to enforce.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Q&A: Lawyer Jeff Gibbs Discusses Implications of Veterinary Drug Case on FDA's LDT, RUO Guidances
January 18, 2012 / Pharmacogenomics Reporter - FDA Keeping All Ideas in Play in Soliciting Public Comments on LDT Regulation
July 21, 2010 / Pharmacogenomics Reporter - At Dx Conference, FDA's Gutierrez Sheds Further Light on Plans for Risk-Based LDT Regulation
September 7, 2011 / Pharmacogenomics Reporter - FDA Mulls Options for Regulating Next-Gen Sequencing Platforms in Clinical Diagnostics
June 29, 2011 / Clinical Sequencing News - FDA Extends LDT Comment Period as Reimbursement Issue Lingers
August 31, 2010 / The Sample